Eli Lilly and Company

Vertex Pharmaceuticals, Inc.

Shu-Hui Chen

James R McCarthy

Xicheng David Sun

Deqi Guo

Nancy June Snyder

Frantz Victor

John Irvin Glass

Mark Joseph Tebbe

Ana Belen Bueno Melendo

Q May Wang

Maria Rosario Gonzalez-Garcia

Jason Eric Lamar

Cristina Garcia-Paredes

Yvonne Yee Mai Yip

Robert Edward Babine

Raymond Samuel Parker, Iii

Ling Jin

Ivan Collado

May Q Wang

Mai Yee Yvonne Yip

Samuel Raymond Parker Iii

Samuel Raymond Iii Parker

Raymond Samuel Iii Parker

Deqi Duo

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Peptidomimetic protease inhibitors

The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation. 

Amides as BACE inhibitors

Growing community of inventors

Carmel, IN, United States of America

Shu-Hui Chen